List of NanoMedicine/Nanotechnology Companies in South Korea - 5

BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

Shaperon is a clinical stage biotech company developing novel inflammasome inhibitors(small molecule). Its unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines including IL-1β, IL-18, IL-6, and TNF-α, etc. by controlling both priming and activation phase of inflammasome, whereas conventional approaches are designed to suppress only the activation phase. With this unique and novel modality which is best suited to address complex immune-mediated inflammatory disorders, we are currently developing multiple clinical programs in atopic dermatitis, cytokine release syndrome, Alzheimer’s disease, ulcerative colitis, NASH, etc. In addition to inflammasome R&D programs, Shaperon has anti-viral, anti-cancer nanobody therapeutics. Shaperon’s proprietary immunized nanobody libraries combined with high throughput screening and in vitro/in vivo system enable us to fast forward the realization of advantages of Nanobodies over conventional antibody-based medicines. We currently developing multi-valent, multi-specific Nanobodies in multiple delivery forms in oncology and viral infection diseases.

At SK bioscience, we work everyday to promote human health from prevetion to cure. We have successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione' through global cooperation with the Bill & Melinda Gates Foundation, CEPI, GSK, etc., and a universal vaccine to prevent ‘Sarbecovirus.’ We have also developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu with obtaining WHO PQ (Pre-qualification) certification in 2019 followed by developing SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. We are expanding our R&D pipeline through global partnerships with public and private institutions, and is planning to commercialize a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine. In addition, SK bioscience signed a CMO contract to manufacture AstraZeneca's COVID-19 vaccine from drug substance to drug product at L-House, SK bioscience’s vaccine manufacturing plant, and contributed to the early prevention of COVID-19, recognized as a global hub for vaccine manufacturing. Based on innovative technology, all pf our colleagues are trying to achieve the company’s mission, ‘We promote human health, from prevention to cure.’ To meet social expectations, SK bioscience will build trust as a global innovative partner of vaccine and biotech so that all stakeholders, including employees, customers, shareholders, and local communities, could be proud and happy.

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.